RT Journal Article
T1 Peripheral Endocannabinoid System Dysregulation in First-Episode Psychosis
A1 Bioque, Miquel
A1 García Bueno, Borja
A1 Mac-Dowell Mata, Karina Soledad
A1 Meseguer, Ana
A1 Saiz, Pilar
A1 Parellada Redondo, María José
A1 Gonzalez-Pinto, Ana
A1 Rodríguez Jiménez, Roberto
A1 Lobo, Antonio
A1 Leza Cerro, Juan Carlos
A1 Bernardo, Miguel
AB Several hypotheses involving alterations of the immune system have been proposed among etiological explanations for psychotic disorders. The endocannabinoid system (ECS) has a homeostatic role as an endogenous neuroprotective and anti-inflammatory system. Alterations of this system have been associated with psychosis. Cannabis use is a robust risk factor for these disorders that could alter the ECS signalling. In this study, 95 patients with a first episode of psychosis (FEP) and 90 healthy controls were recruited. Protein expression of cannabinoid receptor 2 (CB2), the protein levels of the main endocannabinoid synthesizing enzymes N-acyl phosphatidylethanolamine phospholipase (NAPE) and diacylglycerol lipase (DAGL), and of degradation enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) were determined by western blot analysis in peripheral blood mononuclear cells (PBMCs). Patients with a FEP showed a decreased expression of CB2 and of both endocannabinoids synthesizing enzymes (NAPE and DAGL) in comparison to healthy controls. After controlling for age, gender, body mass index, and cannabis use, NAPE and DAGL expression remained significantly decreased, whereas FAAH and MAGL expression were increased. On the other hand, FEP subjects with history of severe cannabis use showed a larger ECS dysregulation compared with healthy controls. These results indicate an ECS dysregulation in PBMC of FEP patients. The alteration of the ECS presented at the initial phases of psychosis could be contributing to the pathophysiology of the disease and constitutes a possible biomarker of psychotic disorders and an interesting pharmacological target to take into account for therapeutic purposes.
PB Springer Nature
SN 0893-133X
SN 1740-634X
YR 2013
FD 2013
LK https://hdl.handle.net/20.500.14352/96737
UL https://hdl.handle.net/20.500.14352/96737
LA eng
NO Bioque M, García-Bueno B, Macdowell KS, Meseguer A, Saiz PA, Parellada M, Gonzalez-Pinto A, Rodriguez-Jimenez R, Lobo A, Leza JC, Bernardo M; FLAMM-PEPs study—Centro de Investigacio´n Biome´dica en Red de Salud Mental. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology. 2013 Dec;38(13):2568-77. doi: 10.1038/npp.2013.165. PMID: 23822951.
NO Ministerio de Economía y Competitividad (España)
NO Centro de Investigación Biomédica en Red de Salud Mental
NO Instituto de Salud Carlos III
NO Comunidad de Madrid
NO Generalitat de Catalunya
NO Esther Koplowitz Center
DS Docta Complutense
RD 18 jul 2024